Researchers have identified that the neutrophil-to-lymphocyte ratio (NLR) during the first week of immunotherapy can predict overall survival in patients with advanced renal cell carcinoma (aRCC). According to a study of 198 patients across 12 Japanese institutions, patients who maintain a high NLR after seven days of treatment face significantly worse outcomes compared to those whose levels drop, offering a potential tool for early clinical risk stratification.
Predicting Survival Through Early NLR Kinetics
The study, which tracked patients with a median follow-up of 18 months, highlights a specific window for prognostic assessment. While baseline (BL) NLR has long been a marker for systemic inflammation, this research indicates that the shift in levels within seven days (D7) of starting immune checkpoint inhibitor combination therapy provides critical data on treatment response.
Patients were categorized based on their NLR trajectory: “low” (BL NLR < 3), “high-low” (BL NLR ≥ 3, dropping below 3 at D7), and “high-high” (BL NLR ≥ 3, remaining ≥ 3 at D7). The data shows that the “high-high” group experienced the poorest survival rates, with 2-year overall survival at 66.0%. In contrast, patients who successfully transitioned from high to low NLR within that first week saw 2-year survival rates similar to those observed in patients who started with low NLR levels.
Did you know?
The research found that while NLR at baseline and day seven were significant predictors of survival, the association weakened by the one-month (M1) mark, suggesting the first week is the most volatile and informative period for clinicians to monitor.
Clinical Implications for Renal Cell Carcinoma Treatment
For oncologists, these findings suggest that the early kinetics of a patient’s immune response—captured simply through blood work—can act as an independent risk factor. Multivariate analysis confirmed that a persistently high NLR is associated with worse overall survival.
Why the First Week Matters
The transition from a high baseline NLR to a lower level within seven days appears to be a favorable indicator of how a patient’s immune system is responding to checkpoint inhibitors.
Frequently Asked Questions
What is the neutrophil-to-lymphocyte ratio (NLR)?
Why is NLR used in cancer research?
In the context of immunotherapy, it helps researchers understand how a patient’s immune profile changes under treatment.
Can NLR replace standard imaging for aRCC?
Are these findings applicable to all immunotherapy patients?
The study specifically focused on patients with advanced renal cell carcinoma treated with first-line immune checkpoint inhibitor combinations.
Are you interested in the latest advancements in oncology biomarkers? Subscribe to our newsletter to receive updates on clinical research and emerging trends in cancer care.
